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Summary] 
We have investigated the possibility of inducing cytotoxic T lymphocytes (CTL) to Ras containing 
a mutation at position 61 or to normal Ras, using recombinant vaccinia viruses expressing these 
proteins.  CTL from C57B1/10 mice immunized with vaccinia  expressing mutant  Ras showed 
specificity for the mutant Ras protein and recognition of normal Ras was inefficient.  The opposite 
specificity was observed after immunization  with vaccinia expressing normal  Ras,  since CTL 
isolated from these mice recognized normal  Ras well and mutant  Ras inefficiently.  Levels of 
endogenous Ras expression were insufficient for lysis by these CTL. One CTL epitope mapped 
to amino acids 60-67 and residue 61 was critical for T cell recognition.  CTL generated against 
mutant Ras protein recognized peptide 60-67 containing mutant residue 61, while anti-normal 
Ras CTL recognized the wild-type 60-67 sequence. A second epitope mapped to residues 152-159 
of Ras and was recognized equally well by CTL raised to normal or mutant  Ras. The murine 
data raise the possibility of exploiting Ras-specific CTL for targeted immunotherapy of certain 
human  cancers. 
T 
he concept of immunotherapy of cancer rests on the ac- 
tivation of effector mechanisms that can specifically recog- 
nize and eliminate  tumor cells.  Since CTL are responsible 
for tumor rejection in many experimental models (1),  they 
represent promising anticancer effectors. The limited success 
of reintroducing cytokine-activated lymphocytes into cancer 
patients might be due to the lack of specificity (2, 3).  Al- 
though it is possible to isolate CTL from tumor-infiltrating 
lymphocytes that specifically lyse the patients tumor cells (4-7), 
the antigens recognized are usually unknown,  making tar- 
geted therapy a difficult task. Significant progress was made 
recently when the gene encoding a CTL-recognized mela- 
noma antigen was cloned and shown to be expressed in 40% 
of human  melanomas  (8). 
Oncogenes are attractive targets for immune intervention 
because they are often mutated or overexpressed in cancer 
cells (9).  The  Ras protein  is implicated in a large number 
of human malignancies,  contributing  to transformation  by 
abnormally high levels of expression (10-12) or through mu- 
tations  at either position  12,  13,  or 61 (13-15).  Although 
MHC class II-restricted Th cells have been generated to syn- 
thetic Ras peptides (16-19), it remained unclear whether these 
T cells can recognize cells expressing Ras endogenously. Since 
Ras is not a secreted or cell surface protein and not known 
to  be present  in  the  endo-lysosomal compartment  where 
loading of MHC class II molecules normally occurs (20), pre- 
sentation to Th cells might be very inefficient.  In contrast, 
the cytoplasmic location of Ras may allow ready access to 
the MHC class I presentation pathway (21), which is required 
for CTL recognition.  In this study we have tested whether 
peptide epitopes derived from endogenously expressed Ras 
are presented by class I molecules and whether they stimu- 
late CTL responses. 
Materials  and Methods 
Cell Lines.  ILMA  is a gauscher virus-induced T cell lymphoma 
of C57BL/6 origin, and R.MA-S is a mutagenized, anti-H-2-selected 
subline of RMA (22). EL4 is a mutagen-induced T cell lymphoma 
isolated from C57BL/6 mice (23). P1HTR is a subline of the P815 
mastocytoma of DBA/2 origin selected for high transfection fre- 
quency (24). P1HTR ceils were transfected with a genomic clone 
of H-2K  b, and P1HTR-D  b transfectants were a gift from E. Simp- 
son (Clinical Research Center, Harrow, London, UK). EL4 trans- 
fectants  were  generated  by electroporation  with  the  retroviral 
vector pBabe-Hygro  (gift from Hartmut Land, Imperial Cancer 
Research Fund,  Lincoln's Inn  Field, London,  UK)  containing 
cDNAs encoding normal or 61 mutant human N-Ras (see below) 
under the promoter control of moloney murine leukemia virus LTR. 
After electroporation, hygromycin-resistant clones were isolated and 
tested by Southern blotting for the presence of intact N-ms genes. 
Densitometer  analysis indicated that the normal N-Ras- and the 
mutant N-Ras-transfected  clones used in this study contained ap- 
proximately five gene copies. All the cell lines were maintained in 
RPMI 1640 plus 10% FCS. 
Recombinant Vaccinia Virus.  cDNAs encoding human N-Ras or 
1493  J.  Exp.  Med.  @ The Rockefeller  University Press ￿9 0022-1007/93/05/1493/06  $2.00 
Volume  177  May  1993  1493-1498 A  B 
Anti-Rn61  CTL  AntI-Ras  CTL 
lo  e"~,~  T.rg.,.  io  Q~  T.rget, 
~.  ~.  RMA§ 
--  ~  ~  RMA+vacE7  ~_  ~.  RMA+vacRm61 
10  10 
50:';  26:';  ~2:'I  6:1  '~:I  L$:1  SO:I  25:1  12"~  e:l  3:';  ';.5:1 
| 
|  40.  "i 
,I. 
~  ,~. 
i 
C 
# 
10" 
0 
AntI.Rn61  CTL 
Targets 
EL4-Ras 
~.  EL4 P.as61 
~  EL4 
~:,  1i:1  5;1  ~,  1.;.1  o.75.1 
E:T  Ratio 
D 
AntI-Rn  CTL 
~E  Targets 
L4 
25:1  12:1  61  3:1  1.5:1  0.75"1 
E:T Ratio 
40 
i  30 
20 
# 
10 
E 
AntI-Ras61  CTL 
3.'1s  0"25  1s  2'6  ~o 
Antibody Cone (pM) 
Antt-CID6 
AnI|-CD4 
Figure  1.  CD8 § CTL lyse Ras- 
expressing target cells. Ras-specific 
CTL were isolated from C57Bl/10 
mice immunized with Vac-P,  as  ~t or 
with Vac-Ras. Target cells are R_MA 
(H-2  b) infected with the indicated 
vaccinia viruses (A and B), or EL4 
(H-2')  transfected  with  Ras 6]  or 
normal Ras (C and D). E shows lysis 
of P,  MA cells infected  with Vac- 
Ras  61 in the presence of mAb to 
CD8 (YTS 169.4) or CD4 (GK1.5). 
CTL activity in the presence of CD4 
antibodies was the same as without 
antibodies (not shown). 
N-Ras with a glutamine to lysine mutation  at position 61  (gifts 
from  Alan  Hall,  Institute  of Cancer  Research,  Chester  Beatty, 
London, UK) were inserted into the vaccinia expression plasmid 
pSCII,  and  recombinant  virus was  generated  as  described  (25). 
Recombinant  virus containing the E7 gene of human  papilloma 
virus (Vac-E7; gift from Lionel Crawford, Department of Pathology, 
Cambridge  University, Cambridge,  UK) was used as control in 
CTL  assays. 
CTL Generation.  2  x  107 PFU of recombinant virus Vac-Ras 
or Vac-Ras  61 was used to immunize C57B1/10 mice (obtained from 
the  ICRF breeding colony at Clare Hall, London,  UK)  by in- 
traperitoneal injection. Mice were boosted with the same virus dose 
2 and 3 wk later. 10 d after the last boost splenocytes were restimu- 
lated  for  5  d  in  10-ml cultures  containing  5  x  107  responder 
spleen cells and 106 stimulator RMA cells infected with Vac-Ras 
or Vac-Ras  61, respectively. CTL lines were established by weekly 
stimulation of responding T  cells in 2-ml cultures containing  8 
￿  10  s T cells, l0  s infected RMA stimulators, and 2  x  106 irradi- 
ated (3,000  tad) syngeneic feeder splenocytes. 
CTL Assays.  CTL activity was tested in standard 4-h StCr re- 
lease assays using SlCr-labeled target cells as described (26). Briefly, 
RMA  or EL4 cells were SlCr labeled for  1 h  at 37~  and  then 
seeded at 5  x  103 per well in 96-well microtiter plates. Effector 
CTL were added to obtain indicated E/T ratios, and after a 4-h 
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vested and radioactivity was counted in a gamma counter (Phar- 
macia/LKB). Percent specific  lysis was calculated using the equa- 
tion: 100x [(experimental  release -  spontaneous  release)/(maximal 
release  -  spontaneous release)]. RMA target cells were infected 
with Vac-Ras, Vac-Ras  6~, or Vac-E7 (10 PFU/cell) for 3 h at 37~ 
before labeling with S~Cr. In  antibody inhibition  experiments, 
anti-CD8 and anti-CD4 mAbs were present during the 4-h CTL 
assay at the indicated concentrations. 
Antibodies.  mAbs Y3 (27) (anti-K  b) and B22 (28) (anti D  b) 
were gifts from Dr. A. Townsend (Institute of Molecular Medi- 
cine, John Radcliffe Hospital, Oxford, UK). For FACS  |  staining 
(Becton Dickinson & Co., Mountain View, CA), undiluted cul- 
ture supernatants were used. mAbs to CD8 (YTS 169.4 [29]) or 
CD4 (GK1.5 [30]) were used for CTL blocking experiments. 
Peptides.  Ras peptides P60  N (GQEEYSAM) P60  ~  (GKEEY- 
SAM) correspond to amino acids 60-67 of  normal or mutant N-Ras, 
respectively, and  P152 (VEDAFYTL)  represents amino  acids 
152-159. Peptide nucleoprotein (NP) 345-360 corresponds to a 
Kb-binding epitope present in  the  nuclear protein of influenza 
virus, and peptide NP366-374 is a Db-binding epitope (31). Pep- 
tide E-7 20-28 corresponds to a Kb-binding  epitope in the E7 pro- 
tein of human papilloma virus (32). All peptides were synthesized 
by the ICR.F Central  Laboratory Services with free NH~- and 
COOH-terminal  ends using solid phase Fmoc chemistry, and their 
purity was analyzed by HPLC and mass spectrometry. 
MHC Class I Binding Assay.  RMA-S  cells  were cultured at 26~ 
overnight to upregulate levels of  class I expression (33). Cells were 
seeded in triplicates on 96-well plates (2  x  10  ~  cells/well), and Ras 
peptides or K  b or D  ~ binding control peptides were added. After 
incubation for I h at 37~  levels of class I expression were deter- 
mined by indirect immunofluorescence  staining and FACS  |  anal- 
ysis as described (32). 
Results and Discussion 
Since vaccinia virus has been shown to be efficient in in- 
ducing CTL responses  (34-36), we have chosen to use this 
vector for stimulation of anti-Ras responses in C57B1/10 mice. 
DNAs encoding normal human N-Ras or mutant N-Ras con- 
taining a glutamine to lysine change at position 61 were in- 
serted into the vaccinia genome and expressed from the early- 
late 7.5 promoter. Mice were immunized and boosted twice 
and spleen cells were restimulated in vitro with infected stimu- 
lator cells. 
CTL lines from animals immunized with Vac-Ras  6t lysed 
H-2b-derived  R.MA  cells  infected  with  the  immunizing 
virus more efficiently than Vac-Ras-infected cells (Fig. 1 A), 
while CTL from Vac-Ras-immune mice lysed targets ex- 
pressing Ras better than Ras6t-expressing  cells (Fig.  1 B). 
Target cells infected with a control vaccinia  construct ex- 
pressing the E7 protein of human papilloma virus showed 
only background lysis, indicating that vaccinia-encoded pro- 
teins did not stimulate detectable CTL responses.  The ob- 
served Ras-specific lysis was mediated by CD8 + T cells since 
anti-CD8 but not anti-CD4 mAbs inhibited lysis (Fig. 1 E). 
CTL lysis was not dependent upon vaccinia infection but was 
also  seen with transfected target cells.  Ras6~-specific CTL 
lysed EL4 cells transfected with Ras  6~ well and showed little 
lysis of target cells transfected with normal Ras (Fig.  1 C). 
Conversely,  Ras  hut  not  Ras  6t  transfectants  were  lysed 
efficiently by CTL raised against normal Ras (Fig. I D). These 
CTL did not lyse untransfected EL4 cells, indicating that levels 
of endogenous Ras expression were insufficient for CTL rec- 
ognition. 
To map the epitopes recognized by Ras-specific CTL lines, 
we took advantage of known peptide binding motifs for the 
MHC class I molecules K b and D b (37). Two K  ~ but no D b 
motifs were present in the Ras sequence. Amino acids 60-67 
contained a  K b motif and we  synthesized 8mer  peptides 
P60  N and P60 ~ corresponding to the normal or mutant Ras 
sequence,  respectively.  Peptide P152, containing the second 
K ~ motif spanning amino acids 152-159,  was also synthe- 
sized.  First, binding to class I molecules was measured in 
a cell surface binding assay (32) using the peptide loading- 
deficient cell line RMA-S. All three Ras peptides bound to 
K b but not D b (Fig.  2), demonstrating the value of predic- 
tive  binding  motifs.  CTL  generated  against  Ras  6~  lysed 
target cells pulsed with P60 ~ well and showed some cross- 
recognition of peptide P60 N (Fig.  3 A), while CTL raised 
against normal Ras recognized P60 N and showed little cross- 
recognition of P60 ~ (Fig. 3 B). Both CTL recognized target 
cells pulsed with peptide P152 equally well (Fig.  3, C  and 
D). As expected, CTL recognition of P60 and P152 was K h 
restricted, which was confirmed by lysis of K ~- but not D ~- 
transfected H-2  a target cells (Fig. 3, E and F). The responses 
of C57B1/10 mice to these epitopes were not due to species 
differences of human and mouse N-Ras, since they are iden- 
tical except for three COOH-terminal residues, 168, 184, and 
188  (38). 
Together, the data show that C57B1/10 mice can generate 
CTL responses  to Ras and that at least  two Kb-restricted 
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Figure 2.  MHC class I binding of Ras peptides. Ras peptides P60N, 
P60M,  and P152 stabilize K  b (A) but not D b (B) class I molecules in 
temperature-induced RMA-S cells. For comparison, the stabilizing effects 
of known Kb-binding peptides NP345  (31) and E7-20 (32) are shown. 
NP366 (31) served as positive control for D b binding. All peptides were 
used at a concentration of 50 #M. In the absence of class 1-binding pep- 
tides expression  of temperature-induced  molecules (26~  samples) decreased 
significantly (37~  samples). All samples were done in triplicate and stan- 
dard deviations are shown. 
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Figure 3.  Recognition  of gas 
peptides P60  N, P60  M, and P152 by 
anti-Ras CTL. SlCr-labeled RMA 
cells (H-2  b) or P1HTR cells (H-2  d) 
transfected with K  b or D  b were in- 
cubated for I h at 37~  with 50 ~tM 
of the indicated peptides and then 
used as targets in a 4-h slCr release 
assay. CTL were from C57B1/10 
mice immunized with Vac-Ras  61 or 
with Vac-Ras. 
epitopes were recognized. This indicates that endogenous Ras 
does not lead to clonal deletion of Ras-specific T  cells.  One 
possibility is that physiologic levels of Ras expression are im- 
munologically silent because they are insu~cient  for T  cell 
recognition. This is supported by the observation that effector 
CTL  only recognized  Ras-transfected  or  Vac-Ras-infected 
targets,  but  not  unmanipulated  cells.  We are not aware of 
a H-2  b tumor cell line overexpressing spontaneously mutant 
or normal Ras,  to test whether transforming levels of Ras 
expression would lead to CTL lysis. In vivo tumor challenge 
experiments with Ras transfectants will reveal whether anti- 
Ras CTL can mediate tumor protection in mice. The selec- 
tive lysis of cells expressing high levels of Ras might allow 
the design of a CTL-based immunotherapy of certain human 
tumors.  Recognition of transformation-associated Ras mu- 
tations would confer strict tumor spedficity to CTL. Although 
the recognition of a mutation-containing epitope in C57B1/10 
mice is very promising, in an outbred human population the 
CTL-recognized epitopes will dearly depend upon the MHC 
haplotype. Nevertheless, the results obtained in the routine 
system encourage the search for Ras epitopes recognized by 
human  CTL. 
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